Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 3/20 | 0.72 |
| ▸ | RCOR1 | Q9UKL0 | 2/20 | 0.72 |
| ▸ | KEAP1 | Q14145 | 3/20 | 0.45 |
| ▸ | TERF2 | Q15554 | 1/20 | 0.43 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.42 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.42 |
| ▸ | ITGAV | P06756 | 1/20 | 0.42 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.42 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.42 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.41 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.40 |
| ▸ | CTSG | P08311 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25455822 | 0.95 | KDM1A (0.77) | KDM1ARCOR1KEAP1TERF2 | |
| SCHEMBL20366251 | 0.95 | KDM1A (0.77) | KDM1ARCOR1KEAP1TERF2 | |
| SCHEMBL25466596 | 0.95 | KDM1A (0.77) | KDM1ARCOR1KEAP1TERF2 | |
| SCHEMBL25455642 | 0.95 | KDM1A (0.77) | KDM1ARCOR1KEAP1TERF2 | |
| SCHEMBL21610478 | 0.91 | KDM1A (0.70) | KDM1ARCOR1KEAP1TERF2 | |
| SCHEMBL21335108 | 0.91 | KDM1A (0.82) | KDM1ARCOR1KEAP1TERF2 | |
| SCHEMBL16426294 | 0.91 | KDM1A (0.82) | KDM1ARCOR1KEAP1TERF2 | |
| SCHEMBL21788721 | 0.90 | KDM1A (0.70) | KDM1ARCOR1KEAP1TERF2 | |
| SCHEMBL25466527 | 0.90 | KDM1A (0.67) | KDM1ARCOR1TERF2 | |
| SCHEMBL21258418 | 0.88 | KDM1A (0.81) | KDM1ARCOR1KEAP1TERF2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230141981-A1 | NOVEL COMPOUNDS AND COMPOSITION FOR TARGETED THERAPY OF KIDNEY-ASSOCIATED CANCERS | Shanghai MICURX Pharmaceuticals Co., Ltd. (CN) | 2023-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230141981-A1 | NOVEL COMPOUNDS AND COMPOSITION FOR TARGETED THERAPY OF KIDNEY-ASSOCIATED CANCERS | GLS, ATP6V1B1, KRAS | KDM1A 3592/4885RCOR1 4682/4885KEAP1 191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.